Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Gliosarcoma with melanocytic differentiation.

Mohanpal S Dulai¹, Gregory S Moes, Anita L Briley

¹Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA.

Acta Neuropathologica

|July 21, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cutaneous Hemangioma With Epithelioid Features Harboring a TPM4::ALK Fusion.

Journal of cutaneous pathology·2026

Same author

Diffuse pediatric-type high grade glioma, RTK1 subtype, subclass C with <i>SYN2</i>::<i>PPARG</i> fusion in an older adult.

CNS oncology·2026

Same author

Corrigendum: <i>O</i> <sup>6</sup>-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances <i>in vitro</i> clonogenicity, tumor implantation <i>in vivo</i>, and <i>sensitivity</i> to alisertib-carboplatin combination treatment.

Frontiers in cellular neuroscience·2025

Same author

O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances <i>in vitro</i> clonogenicity, tumor implantation <i>in vivo</i>, and sensitivity to alisertib-carboplatin combination treatment.

Frontiers in cellular neuroscience·2025

Same author

Frontal lobe intra-axial schwannoma harboring a CHD7::VGLL3 fusion and heterozygous TSC2 p.F1510del mutation in a young child.

Molecular biology reports·2025

Same author

Papillary tumor of the pineal region: analysis of DNA methylation profiles and clinical outcomes in 76 cases.

Acta neuropathologica communications·2024

This study describes a rare gliosarcoma with melanocytic differentiation in a 65-year-old man. Recognizing this unusual tumor is crucial to avoid misdiagnosing it as metastatic melanoma.

Area of Science:

Neuro-oncology
Dermatopathology
Tumor Biology

Background:

Gliosarcomas are rare malignant brain tumors characterized by a biphasic pattern of glial and sarcomatous elements.
Melanocytic differentiation is a known phenomenon in some central nervous system (CNS) neoplasms, including medulloblastomas and rare glial tumors.
Distinguishing primary CNS tumors with divergent differentiation from metastatic disease is critical for accurate diagnosis and treatment.

Observation:

A unique case of gliosarcoma was identified in a 65-year-old male patient.
The gliosarcoma exhibited numerous islands of well-differentiated melanocytes, a feature not previously reported in this specific tumor type.
Histological examination and immunophenotyping were employed to characterize the tumor components.

Findings:

Related Experiment Videos

This case represents the first documented instance of a gliosarcoma demonstrating melanocytic differentiation.
The presence of melanocytic components within the gliosarcoma highlights the potential for divergent differentiation in glial neoplasms.
Immunohistochemical analysis aided in differentiating the glial and melanocytic elements, ruling out metastatic melanoma.

Implications:

Awareness of melanocytic differentiation in gliosarcomas is essential for accurate diagnosis and to prevent misclassification as metastatic melanoma or primary CNS melanocytic neoplasms.
This finding expands the understanding of tumor heterogeneity and differentiation potential within glial tumors.
Further research may elucidate the mechanisms driving melanocytic differentiation in gliosarcomas and its impact on prognosis.